Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay
Lipson D, Nahas MK, Otto GA, et al.
Key Points:
Current clinical genomic profiling platforms only capture small set of known somatic alterations
Authors describe newly developed, highly sensitive genomic profiling assay for clinical sequencing of frozen/paraffin samples of hematological malignancies
Assay also highly specific and able to identify additional clinically relevant mutations in JAK2, FLT3 and IDH2
Implications:
- Novel tool represents very sensitive and specific genomic profiling platform for identifying mutations with clinical relevance in broad spectrum of hematologic malignancies
View the original abstract on the ASH website.
